VIAL
Compound comparison

FOXO4-DRI vs Sermorelin

FOXO4-DRI and Sermorelin are both peptide compounds evaluated on Vial: FOXO4-DRI is ruo with preclinical evidence, and Sermorelin is legally compoundable with clinical-trial evidence.

Vial summary · compiled from public records

At a glance

FOXO4-DRI

Category
Peptide
FDA / legal status
RUO
Route
0providers on Vial →

Sermorelin

Category
Peptide
FDA / legal status
Legally Compoundable
Route
Subcutaneous
27providers on Vial →

Side by side

FieldFOXO4-DRISermorelin
CategoryPeptidePeptide
Brand names
FDA / legal statusRUOLegally Compoundable
Evidence tierPreclinicalClinical Trials
Administration routeSubcutaneous
Compounding accessRUOLegally Compoundable
Providers on Vial0 listed27 listed
Typical price bandVaries by provider$ to $$$

Verified providers offering each

Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+70 to 8450 to 69Under 50

About each compound

About FOXO4-DRI

FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic stapled peptide senolytic developed by de Keizer et al. (Nature Medicine, 2017). It disrupts the FOXO4–p53 interaction that keeps senescent cells alive, triggering apoptosis selectively in senescent cells. In mice, systemic administration reversed doxorubicin-induced liver damage, restored hair density in naturally aged mice, and improved fitness metrics. It has no FDA approval for human use and has not entered human clinical trials. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards.

About Sermorelin

A synthetic analog of growth hormone-releasing hormone (GHRH), this 29-amino acid peptide stimulates the pituitary gland to produce and secrete endogenous growth hormone through binding to GHRH receptors. It functions by mimicking the N-terminal bioactive portion of native GHRH, promoting pulsatile GH release while preserving the body's natural feedback mechanisms. Primary applications include diagnostic testing of pituitary function and therapeutic use in growth hormone deficiency.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →